Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jan 2007

Agaram Narasimhan P, Besmer Peter, Wong Grace C, Guo Tianhua, Socci Nicholas D, Maki Robert G, DeSantis Diann, Brennan Murray F, Singer Samuel, DeMatteo Ronald P, Antonescu Cristina R

Abstract excerpt

PURPOSE: Gastrointestinal stromal tumor (GIST) is the most common sarcoma of the intestinal tract. Nearly all tumors express KIT protein, and most have an activating mutation in either KIT or PDGFRA. Therapy with selective tyrosine kinase inhibitors achieves a partial response or stable disease i...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Gastrointestinal Stromal Tumors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Microscopy, Electron

Share to Piperazines

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins c-kit

Share to Pyrimidines

Source

Identifiers

PMID: 17200352
DOI: 10.1158/1078-0432.CCR-06-1508

Genes

KIT
PDGFRA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17200352-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.PMID 17200352Read ↗

Gastrointestinal stromal tumors: overview of pathologic features, molecular biology, and therapy with imatinib mesylate.Semantic proximity Read ↗

Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site.Semantic proximity Read ↗

Gastrointestinal stromal tumor: Recent advances in pathology and geneticsSemantic proximity Read ↗

KIT mutations and expression: current knowledge and new insights for overcoming IM resistance in GIST.Semantic proximity Read ↗

Emerging Targeted Therapeutic Strategies to Overcome Imatinib Resistance of Gastrointestinal Stromal Tumors.Semantic proximity Read ↗

Gastrointestinal stromal tumors (GISTs): from science to targeted therapy.Semantic proximity Read ↗

Progress in determining response to treatment in gastrointestinal stromal tumor.Semantic proximity Read ↗

KITlow Cells Mediate Imatinib Resistance in Gastrointestinal Stromal TumorSemantic proximity Read ↗

Functional features of gene expression profiles differentiating gastrointestinal stromal tumours according to KIT mutations and expression.Semantic proximity Read ↗

Surgical Pathology of Gastrointestinal Stromal Tumors: Practical Implications of Morphologic and Molecular Heterogeneity for Precision Medicine.Semantic proximity Read ↗

Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up.Semantic proximity Read ↗

Multiomic Landscape of Gastrointestinal Stromal Tumors in a Real-World Patient Cohort of 1,427 Cases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.